Recent studies on colchicine hybrids, such as SBN-284, have shown its dual action in inhibiting cholinesterase activity and suppressing NLRP3 inflammasome activation, making it a promising candidate for addressing both cholinergic dysfunction and neuroinflammation in AD [54]. This evidence concerns the gene NLRP3 and Alzheimer disease.